跳至主要内容
临床试验/NL-OMON52890
NL-OMON52890招募中2 期

Deferoxamine in Aneurysmal Subarachnoid Hemorrhage trial - DASH

Radboud Universitair Medisch Centrum0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 18-85 years old inclusive,
  • Subarachnoid hemorrhage diagnosed by CT on admission,
  • No history of possible traumatic origin of subarachnoid hemorrhage,
  • Eligible for inclusion within 72 hours of subarachnoid hemorrhage,
  • Saccular intracranial aneurysm proven by cerebral angiography or CTA,
  • Surgical or endovascular obliteration is successfully performed,
  • Able to obtain written informed consent from patient or surrogate,
  • Patients in good clinical grade (WFNS 1-3) (GCS 13-15) at time of inclusion.

排除标准

  • Pregnancy, as confirmed by routine urine test on admission,
  • Abnormal renal function at time of inclusion (eGFR <60 mL/min/1.73m2)
  • Elevated liver function test at time of inclusion (AST > 35 U/L and ALT > 45
  • History of liver disease or active liver or renal disease,
  • Patients with low ferritine (< 20 µg/L),
  • Hypersensitivity to deferoxamine,
  • Patient taking medication not recommended for concomitant use with
  • deferoxamine as per the product label (e.g. high dose vit. C medication).
  • Patients not able to complete the study follow-up.
  • The presence of 4 or more of the following risk modifiers for ARDS prior to
  • enrollment:
  • o Tachypnea (respiratory rate >30),
  • o SpO2 <95%,
  • o Obesity (BMI >30)
  • o Acidosis (pH <7.35),
  • o Hypoalbuminemia (albumin <3.5 g/dL),
  • o Concurrent use of chemotherapy

研究者

相似试验